Table 3

Comparison of baseline characteristics of patients with vs. without Pneumocystis pneumonia in no-prophylaxis groupa
Characteristics PCP group Non-PCP group P-value
Patients (n) 9 552
Observation period (person-years) 12.5 839.4
Age (years) 69.5 ± 7.63 57.9 ± 14.1 0.001
Duration of RA (months) 76.3 ± 73.8 112.9 ± 116.5 0.634
DAS28 score (ESR) 6.51 ± 1.28 5.85 ± 1.29 0.060
Coexisting pulmonary disease (%) 77.8 28.1 0.002
Diabetes mellitus (%) 0.00 10.7 0.156
Dose of prednisolone (mg) 8.83 ± 14.9 1.70 ± 2.57 0.004
Glucocorticoids (%)b 88.9 39.9 0.009
Dose of methotrexate (mg/w) 6.56 ± 5.23 7.29 ± 4.10 0.695
Serum level of IgG (mg/dl) 1,600 ± 714 1,620 ± 511 0.660
Serum level of KL-6 (U/ml) 429 ± 218 257 ± 138 0.008

aDAS28: Disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation rate; IgG: immunoglobulin G; PCP: Pneumocystis pneumonia; RA: Rheumatoid arthritis. bGlucocorticoid data are percentages of patients treated with glucocorticoids.

Patient age, the complication of pulmonary disease, the use and dose of glucocorticoids and the serum level of KL-6 were significantly different between the two groups. Data are mean ± SD by Wilcoxon rank-sum test unless otherwise specified.

Katsuyama et al.

Katsuyama et al. Arthritis Research & Therapy 2014 16:R43   doi:10.1186/ar4472

Open Data